they already funded the 2a/b trial($20m at $5).Cash will be sufficient to fund the early 2016 data for sure and i believe the second data 6 months later,as well.if the RP-G28 SUCCESS RTTR WILL WORTH MULTI HUNDREDS MILLION DOLLARS,so future funding will be your last worry.
As mentioned before I Decided to bank on RTTR Exactly like Bakers Bros. and other Institutional.
There is NO WAY in Hell they would plop down $20 at $5 per share on the treatment for lactose intolerance unless their people did their DD and went over the data. They had to see some very encouraging data they were impressed with.they're gonna want to see at least the $7 price per share to make it worth their while,and there is no way they gonna sell under Purchase price( $5), when they will be able to do that imo.
News 
Market Data 
Discover 
